Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

(2020) Daisuke Yabe et al.   Lancet Diabetes & Endocrinology

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

(2020) Yuichiro Yamada et al.   Lancet Diabetes & Endocrinology

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

(2019) V. R Aroda et al.   DIABETES & METABOLISM

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

(2019) Julio Rosenstock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects

(2019) Tine A. Bækdal et al.   CLINICAL PHARMACOKINETICS

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

(2019) Vanita R. Aroda et al.   DIABETES CARE

Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example

(2019) Vanita R. Aroda et al.   DIABETES OBESITY & METABOLISM

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

(2019) Richard Pratley et al.   LANCET

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2019) Mansoor Husain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

(2019) Thomas R Pieber et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

(2019) Bernard Zinman et al.   DIABETES CARE

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETOLOGIA

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment

(2018) Charlotte Granhall et al.   CLINICAL PHARMACOKINETICS

A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide

(2018) Tine A. Bækdal et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

(2018) Tine A. Baekdal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The kidney and cardiovascular outcome trials

(2018) Zachary Bloomgarden   Journal of Diabetes

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes

(2018) Charlotte Granhall et al.   CLINICAL PHARMACOKINETICS

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

(2018) Stephen C. Bain et al.   DIABETES OBESITY & METABOLISM

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(2018) Adrian F Hernandez et al.   LANCET

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

(2018) Stephen T. Buckley et al.   Science Translational Medicine

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes

(2017) Melanie Davies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives

(2016) Yutaka Seino et al.   Journal of Diabetes Investigation

Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

(2013) E. R. Seaquist et al.   DIABETES CARE

Approaches for enhancing oral bioavailability of peptides and proteins

(2013) Jwala Renukuntla et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Glucagon-like peptide 1 and appetite

(2013) Megan J. Dailey et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B12 Formulation and Intermittent Intramuscular Vitamin B12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-Group Study

(2011) M. Cristina Castelli et al.   CLINICAL THERAPEUTICS

Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease

(2011) R. E. Schmieder et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY